日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104)

新辅助信迪利单抗联合化疗治疗 EGFR 突变型非小细胞肺癌:2 期试验中期结果 (NEOTIDE/CTONG2104)

Chao Zhang ,Yu-Xuan Sun ,Ding-Cheng Yi ,Ben-Yuan Jiang ,Li-Xu Yan ,Ze-Dao Liu ,Li-Shan Peng ,Wen-Jie Zhang ,Hao Sun ,Zhi-Yong Chen ,Dan-Hua Wang ,Di Peng ,Song-An Chen ,Si-Qi Li ,Ze Zhang ,Xiao-Yue Tan ,Jie Yang ,Zhang-Yi Zhao ,Wan-Ting Zhang ,Jian Su ,Yang-Si Li ,Ri-Qiang Liao ,Song Dong ,Chong-Rui Xu ,Qing Zhou ,Xue-Ning Yang ,Yi-Long Wu ,Ze-Min Zhang ,Wen-Zhao Zhong

Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study

使用患者来源的类器官预测局部晚期或转移性肺癌肿瘤反应:一项真实世界研究

Han-Min Wang, Chan-Yuan Zhang, Kai-Cheng Peng, Ze-Xin Chen, Jun-Wei Su, Yu-Fa Li, Wen-Feng Li, Qing-Yun Gao, Shi-Ling Zhang, Yu-Qing Chen, Qing Zhou, Cong Xu, Chong-Rui Xu, Zhen Wang, Jian Su, Hong-Hong Yan, Xu-Chao Zhang, Hua-Jun Chen, Yi-Long Wu, Jin-Ji Yang

Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer

肝转移中的免疫抑制微环境有助于晚期非小细胞肺癌免疫治疗的器官特异性反应

Jia-Yi Deng #, Qing Gou #, Lingling Yang, Zhi-Hong Chen, Ming-Yi Yang, Xiao-Rong Yang, Hong-Hong Yan, Xue-Wu Wei, Jia-Qi Liu, Jian Su, Wen-Zhao Zhong, Chong-Rui Xu, Yi-Long Wu, Qing Zhou

The tomato OST1-VOZ1 module regulates drought-mediated flowering

番茄OST1-VOZ1模块调控干旱介导的开花

Leelyn Chong,Rui Xu,Pengcheng Huang,Pengcheng Guo,Mingku Zhu,Hai Du,Xiaoli Sun,Lixia Ku,Jian-Kang Zhu,Yingfang Zhu

Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial

前瞻性临床试验中对 EGFR-L858R 突变肺癌患者对 EGFR-TKI 的疗效和耐药性的连续 cfDNA 评估

Qing Zhou, Jin-Ji Yang, Zhi-Hong Chen, Xu-Chao Zhang, Hong-Hong Yan, Chong-Rui Xu, Jian Su, Hua-Jun Chen, Hai-Yan Tu, Wen-Zhao Zhong, Xue-Ning Yang, Yi-Long Wu